Fairvalue-Calculator Fairvalue-Calculator
EN DE

VYNE Therapeutics Inc (VYNE) Fair Value & Analysis

Healthcare · US · Market cap $21.7M

Price$0.6506
Fair Value$3.74
Upside+474.9%
Quality95/100
Evidence: Low Range $2.81 – $4.68

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

VYNE Therapeutics Inc (VYNE) currently trades at $0.6506, while our model-based Fair Value estimate is $3.74 — implying the stock looks roughly 474.9% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor in Phase 1b trial for the acute control and chronic management of immune-mediated inflammatory conditions. VYNE Therapeutics Inc. was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. The company was founded in 2003 and is based in Stewartsville, New Jersey.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -84% Regeneron Pharmaceuticals, Inc (REGN) +109% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -64%

Frequently asked questions

Is VYNE Therapeutics Inc (VYNE) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $3.74 versus a price of $0.6506 — about +475% (undervalued). Model-based estimate, not financial advice.
What is the fair value of VYNE?
Our 21-model fair value for VYNE Therapeutics Inc is $3.74 (as of Jun 25, 2026), built from audited fundamentals. The current price is $0.6506.
What is the quality score of VYNE?
VYNE Therapeutics Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.